Walleye Capital’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$428K Buy
29,300
+25,000
+581% +$330K ﹤0.01% 2883
2026
Q1
$59.3K Sell
4,300
-2,300
-35% -$34.7K ﹤0.01% 3850
2025
Q4
$119K Sell
6,600
-18,000
-73% -$323K ﹤0.01% 3805
2025
Q3
$456K Buy
24,600
+13,000
+112% +$204K ﹤0.01% 2690
2025
Q2
$186K Buy
11,600
+11,500
+11,500% +$205K ﹤0.01% 3420
2025
Q1
$1.94K Sell
100
-17,800
-99% -$375K ﹤0.01% 4133
2024
Q4
$394K Buy
17,900
+10,300
+136% +$198K ﹤0.01% 3188
2024
Q3
$128K Buy
+7,600
New +$113K ﹤0.01% 4283

Other funds holding CLBT

Walleye Capital's CLBT Position: Q2 2026 in Review

Walleye Capital opened a new position in Cellebrite (CLBT) in Q2 2026: 30 shares worth $438. The stake represents ﹤0.01% of the portfolio and ranks #4620 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CLBT as recently as Q4 2025.

Walleye Capital first reported a position in CLBT in Q4 2023 and has held it in 10 quarters since. The position peaked at $20M in Q3 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Walleye Capital held 30 shares of Cellebrite worth $438 as of Q2 2026.
  • Cellebrite was a new Walleye Capital position in Q2 2026.
  • Cellebrite made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4620 holding.
  • Walleye Capital first reported a position in Cellebrite in Q4 2023 and has held it in 10 quarters since.
  • Walleye Capital's Cellebrite position peaked at $20M in Q3 2024.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.